Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Fore

Surgery Southaven, MS Medical Doctor

NPI 1407969843 CMS profile 154921

401 Southcrest Cir, Suite 210, Southaven, MS 38671

Open in the dashboard

General payments

$254,019

280 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Fore of Southaven, MS is reported in the CMS Open Payments database as having received $254,019 across 280 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,759 56
2024 General $17,579 16
2023 General $51,057 49
2022 General $39,560 51
2021 General $37,417 43
2020 General $36,533 39
2019 General $11,113 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Fore
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Daniel Fore were reported at $60,759. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Daniel Fore Surgery median Middle half National median
2019 $11,113 $253 $82–$1,521 $163
2020 $36,533 $131 $40–$706 $114
2021 $37,417 $168 $50–$904 $132
2022 $39,560 $224 $76–$1,218 $149
2023 $51,057 $253 $82–$1,255 $160
2024 $17,579 $279 $90–$1,381 $164
2025 $60,759 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $248,896 244 payments
  2. Medical Device Business Services, Inc. $4,371 9 payments
  3. TELA Bio, Inc. $184 3 payments
  4. Davol Inc. $155 3 payments
  5. Acera Surgical, Inc. $52 2 payments
  6. Innovation Technologies Inc $42 1 payment
  7. Pacira Pharmaceuticals Incorporated $34 2 payments
  8. Integra LifeSciences Corporation $31 1 payment
  9. Z-Medica, LLC $28 1 payment
  10. ConvaTec Inc. $22 1 payment
  11. Other $204 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $217,300 58 payments
  2. Food and Beverage $19,929 159 payments
  3. Travel and Lodging $8,600 52 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,000 8 payments
  5. Consulting Fee $3,160 1 payment
  6. Gift $30 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $246,396 241 payments
  2. ECHELON ENDOPATH Stapler $3,160 1 payment
  3. HARMONIC Product Family $3,160 1 payment
  4. SURGICEL Family of Absorbable Hemostats $3,160 1 payment
  5. DA VINCI SP $2,500 3 payments
  6. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $184 3 payments
  7. Phasix Mesh $135 2 payments
  8. LINX Reflux Management System $115 1 payment
  9. Restrata Wound Matrix $52 2 payments
  10. Irrisept $42 1 payment
  11. Other $545 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

102

Median for General Surgery: 59

Drug cost

$214

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 87 $115
Dicyclomine Hcl Generic 15 $100

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$57,826

Medicare's payments for the services billed

Medicare patients

132

Average age 73

Services billed

261

81 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 39%
Diabetes 31%
Cancer 30%
Chronic kidney disease 27%
Depression 23%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record